通过连续高速全身360°碲锌镉SPECT对转移性前列腺肿瘤从首次至末次[177Lu]Lu-PSMA治疗注射变化的综合分析评估预后价值
本研究纳入72例接受[177Lu]Lu-PSMA-617治疗的转移性去势抵抗性前列腺癌(mCRPC)患者,于每次注射后24小时行18分钟全身360°碲锌镉(CZT)SPECT显像,并用Cox模型分析总生存期(OS)。在57例至少接受2个周期的患者中,仅SPECT检测到新发骨病灶(P<0.0001)和末次SPECT总病灶活性(TLA,P=0.0007)为多因素预测因子;无新发骨病灶且末次TLA低于中位数750 mL·SUV者平均生存19.7个月,仅满足1项者14.4个月,均不满足者6.9个月。
要点
- 在57例至少接受2个[177Lu]Lu-PSMA治疗周期的mCRPC患者中,35例(61%)在末次注射后随访12.0个月(范围4.9-17.5个月)内死亡。
- 多因素分析仅SPECT检测到治疗期间新发骨病灶(P<0.0001)和末次SPECT TLA(P=0.0007)为OS的独立预测因子。
- 无新发骨病灶且末次TLA低于中位数750 mL·SUV的19例患者平均生存19.7个月(95%CI 16.6-22.8),仅满足1项者14.4个月(95%CI 10.9-18.0),均不满足者6.9个月(95%CI 4.5-9.6)。
核心结论
- 通过快速全身360°[177Lu]Lu CZT SPECT记录对首次至末次[177Lu]Lu-PSMA注射的肿瘤变化进行综合分析,可为mCRPC患者提供强有力的预后信息,优于PSA演变和[68Ga]Ga-PSMA-11 PET变量等传统OS预测因子。
研究设计与样本
- 纳入接受[177Lu]Lu-PSMA-617注射治疗的mCRPC患者,治疗前接受[68Ga]Ga-PSMA-11 PET,每次注射后24小时行18分钟全身360°[177Lu]Lu CZT SPECT记录,每次注射前测量血浆PSA。
- 共纳入72例患者,中位年龄71岁(四分位距64-77岁),接受最多6次[177Lu]Lu-PSMA注射。
- 采用Cox比例风险模型预测总生存期(OS),分析PSA演变以及从[68Ga]Ga-PSMA-11 PET和首次及末次[177Lu]Lu SPECT提取的肿瘤SUVmax、SUVmean、总摄取体积和总病灶活性(TLA;总摄取体积×SUVmean)。
主要发现
- 在57例至少接受2个[177Lu]Lu-PSMA治疗周期的患者中,35例(61%)在末次注射后随访12.0个月(范围4.9-17.5个月)内死亡。
- 大多数PSA、PET和SPECT变量为OS的显著单因素预测因子。
- 多因素分析仅选择2个[177Lu]Lu SPECT变量:治疗期间SPECT检测到新发骨病灶(P<0.0001)和末次SPECT TLA(P=0.0007)。
- 无新发骨病灶且末次TLA低于中位数750 mL·SUV的19例患者平均生存19.7个月(95%CI 16.6-22.8个月)。
- 仅满足上述2项标准中1项的19例患者平均生存14.4个月(95%CI 10.9-18.0个月);2项均不满足的19例患者平均生存6.9个月(95%CI 4.5-9.6个月)。
关键数值与推荐
- 多因素预测因子:SPECT检测到治疗期间新发骨病灶(P<0.0001)和末次SPECT TLA(P=0.0007)。
- 末次TLA中位数为750 mL·SUV。
- 无新发骨病灶且末次TLA低于中位数750 mL·SUV者平均生存19.7个月(95%CI 16.6-22.8个月)。
- 仅满足1项标准者平均生存14.4个月(95%CI 10.9-18.0个月);2项均不满足者平均生存6.9个月(95%CI 4.5-9.6个月)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anger SPECT monitoring of [177Lu]Lu-prostate-specific membrane antigen (PSMA) therapy provides significant prognostic information about patients with metastatic castration-resistant prostate cancer (mCRPC) but with 36- to 90-min recording times and partial body coverage. This study assesses the prognostic information from a comprehensive analysis of tumor changes from the first to the last [177Lu]Lu-PSMA therapy injections, as provided by whole-body [177Lu]Lu SPECT recordings from a high-speed 360° cadmium-zinc-telluride (CZT) camera of mCRPC patients. Methods: We included mCRPC patients treated by [177Lu]Lu-PSMA-617 injections who underwent [68Ga]Ga-PSMA-11 PET before treatment, whole-body 360° [177Lu]Lu CZT SPECT recordings of only 18 min obtained 24 h after each [177Lu]Lu-PSMA therapy injection, and plasma prostate-specific antigen (PSA) measurements before each injection. We used Cox proportional hazards models to predict overall survival (OS) according to PSA evolution during treatment, as well as tumor SUVmax, SUVmean, total uptake volume, and total lesion activity (TLA; total uptake volume × SUVmean) extracted from [68Ga]Ga-PSMA-11 PET and the first and last [177Lu]Lu SPECT scans. Results: We included 72 patients with a median age of 71 y (interquartile range, 64-77 y), treated with up to 6 [177Lu]Lu-PSMA injections. Among 57 patients with at least 2 [177Lu]Lu-PSMA treatment cycles, 35 (61%) died during a follow-up of 12.0 mo (range, 4.9-17.5 mo) from the last [177Lu]Lu-PSMA injection. Most PSA, PET, and SPECT variables were significant univariate predictors of OS. However, only 2 [177Lu]Lu SPECT variables were selected as multivariate predictors: SPECT detection of new bone lesions during treatment (P < 0.0001) and final SPECT TLA (P = 0.0007). Means of survival times were 19.7 mo (95% CI, 16.6-22.8 mo) in the 19 patients who showed no new bone lesions and final TLA lower than the median of 750 mL·SUV, 14.4 mo (95% CI, 10.9-18.0 mo) in the 19 patients with only 1 of these 2 criteria, and 6.9 mo (95% CI, 4.5-9.6 mo) in the 19 patients with neither criterion. Conclusion: A comprehensive analysis of tumor changes from the first to the last [177Lu]Lu-PSMA injections, obtained with fast whole-body 360° [177Lu]Lu CZT SPECT recordings, provides strong prognostic information about mCRPC patients, outperforming conventional OS predictors such as PSA evolution and [68Ga]Ga-PSMA-11 PET variables before treatment.
引用
- Kunsch J, Zaragori T, Olivier P, et al. Prognostic Value of Comprehensive Analysis of Metastatic Prostate Tumor Changes from First to Last [177Lu]Lu-PSMA Therapy Injections Through Serial High-Speed Whole-Body 360° Cadmium-Zinc-Telluride SPECT. J Nucl Med. 2025. PMID: 40935614. doi:10.2967/jnumed.125.270358
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。